Biovica International AB (publ) (BIOVIC-B.ST)
SEK 1.62
(-8.47%)
SEK 1.62
(-8.47%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.19 Million SEK | 61.93% |
| 2022 | 1.35 Million SEK | -11.36% |
| 2021 | 1.53 Million SEK | 190.7% |
| 2020 | 527 Thousand SEK | 32.75% |
| 2019 | 397 Thousand SEK | -10.99% |
| 2018 | 446 Thousand SEK | 10.67% |
| 2017 | 403 Thousand SEK | 31.27% |
| 2016 | 307 Thousand SEK | -36.44% |
| 2015 | 483 Thousand SEK | 57.33% |
| 2014 | 307 Thousand SEK | -18.03% |
| 2013 | 374.54 Thousand SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 1.87 Million SEK | -14.64% |
| 2023 Q4 | 2.19 Million SEK | -16.48% |
| 2023 Q3 | 2.63 Million SEK | 5.62% |
| 2023 FY | 2.19 Million SEK | 61.93% |
| 2023 Q1 | 2.26 Million SEK | 67.08% |
| 2023 Q2 | 2.49 Million SEK | 9.87% |
| 2022 Q1 | 1.61 Million SEK | 5.35% |
| 2022 Q4 | 1.35 Million SEK | 3.11% |
| 2022 Q2 | 1.41 Million SEK | -12.39% |
| 2022 FY | 1.35 Million SEK | -11.36% |
| 2022 Q3 | 1.31 Million SEK | -6.86% |
| 2021 FY | 1.53 Million SEK | 190.7% |
| 2021 Q2 | 1.11 Million SEK | 145.58% |
| 2021 Q3 | 1.1 Million SEK | -0.18% |
| 2021 Q1 | 452 Thousand SEK | -14.23% |
| 2021 Q4 | 1.53 Million SEK | 38.27% |
| 2020 Q2 | 681 Thousand SEK | 24.5% |
| 2020 FY | 527 Thousand SEK | 32.75% |
| 2020 Q4 | 527 Thousand SEK | -38.79% |
| 2020 Q3 | 861 Thousand SEK | 26.43% |
| 2020 Q1 | 547 Thousand SEK | 37.78% |
| 2019 Q4 | 397 Thousand SEK | -15.89% |
| 2019 FY | 397 Thousand SEK | -10.99% |
| 2019 Q1 | 529 Thousand SEK | 18.61% |
| 2019 Q2 | 272 Thousand SEK | -48.58% |
| 2019 Q3 | 472 Thousand SEK | 73.53% |
| 2018 Q2 | 330 Thousand SEK | -2.37% |
| 2018 FY | 446 Thousand SEK | 10.67% |
| 2018 Q4 | 446 Thousand SEK | -14.07% |
| 2018 Q3 | 519 Thousand SEK | 57.27% |
| 2018 Q1 | 338 Thousand SEK | -16.13% |
| 2017 FY | 403 Thousand SEK | 31.27% |
| 2017 Q1 | 345 Thousand SEK | 12.38% |
| 2017 Q4 | 403 Thousand SEK | -1.71% |
| 2017 Q3 | 410 Thousand SEK | 20.23% |
| 2017 Q2 | 341 Thousand SEK | -1.16% |
| 2016 Q4 | 307 Thousand SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | 307 Thousand SEK | -36.44% |
| 2016 Q2 | 348 Thousand SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | 483 Thousand SEK | 0.0% |
| 2015 Q3 | 483 Thousand SEK | 0.0% |
| 2015 FY | 483 Thousand SEK | 57.33% |
| 2014 FY | 307 Thousand SEK | -18.03% |
| 2013 FY | 374.54 Thousand SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | -109949900.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 152.495% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 130.816% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 85.247% |
| Intervacc AB (publ) | 10.48 Million SEK | 79.023% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | 88060.0% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 93.758% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 75.75% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 112869.231% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 30.19% |
| Saniona AB (publ) | 1.00 SEK | -219899900.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 235.24% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -219899900.0% |
| AcouSort AB (publ) | 2.08 Million SEK | -5.721% |
| Xintela AB (publ) | 398 Thousand SEK | -452.513% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -214.143% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 354.809% |
| Amniotics AB (publ) | 534 Thousand SEK | -311.798% |
| 2cureX AB (publ) | -1000.00 SEK | 220000.0% |
| CombiGene AB (publ) | -1.79 Million SEK | 222.235% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 89.235% |
| Camurus AB (publ) | 100.95 Million SEK | 97.822% |
| Corline Biomedical AB | -3.85 Million SEK | 157.013% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -219800.0% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | 4.28 Million SEK | 48.621% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 77.543% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 144.614% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | -303.311% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 94.977% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 591.962% |
| Nanologica AB (publ) | 2.97 Million SEK | 26.034% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 784.737% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 81.434% |
| Alzinova AB (publ) | -3.27 Million SEK | 167.084% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 9.32% |
| Pila Pharma AB (publ) | 1.00 SEK | -219899900.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 148081.157% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 45.488% |
| Simris Alg AB (publ) | 1.09 Million SEK | -101.558% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 90.857% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 97.942% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -113.911% |